UnknownPhase 2NCT00039156
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Theradex
- Principal Investigator
- Rasim Ahmet Gucalp, MD, MDMontefiore Medical Center
- Intervention
- ortataxel(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2002
Study locations (15)
- Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States
- Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States
- Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- HemOnCare, P.C., Brooklyn, New York, United States
- North Shore University Hospital, Manhasset, New York, United States
- State University of New York - Upstate Medical University, Syracuse, New York, United States
- Albert Einstein Clinical Cancer Center, The Bronx, New York, United States
- New York Medical College, Valhalla, New York, United States
- West Clinic, Memphis, Tennessee, United States
- Seattle Cancer Care Alliance, Seattle, Washington, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Cross Cancer Institute, Edmonton, Alberta, Canada
- St. Paul's Hospital - Vancouver, Vancouver, British Columbia, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00039156 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha